Krystal Biotech grants director options, 471 RSUs

Q: What equity awards did director Dino A. Rossi receive from KRYS on September 14, 2026?

He received stock options for 1,187 shares of Krystal Biotech common stock at an exercise price of $340.03 per share and 471 restricted stock units, each representing a contingent right to one common share.

Q: When do Dino A. Rossi’s new Krystal Biotech (KRYS) stock options and RSUs vest?

Both the stock options and the 471 restricted stock units vest in full on September 14, 2027, subject to his continued service on Krystal Biotech’s Board of Directors and earlier vesting in certain circumstances described in the Non-Employee Director Compensation Policy.

Q: What is the exercise price and expiration date of Dino A. Rossi’s new KRYS stock options?

The newly granted options have an exercise price of $340.03 per share and expire on September 13, 2036, according to Krystal Biotech’s disclosure.

Q: How many Krystal Biotech (KRYS) shares underlie Dino A. Rossi’s new RSU grant?

The restricted stock unit grant covers 471 RSUs, and each RSU represents a contingent right to receive one share of Krystal Biotech’s common stock upon vesting, assuming service conditions are met.

Director Dino A. Rossi received stock options and restricted stock units in Krystal Biotech as part of non-employee director compensation.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Krystal Biotech, Inc. (KRYS) reported that director Dino A. Rossi received new equity awards on September 14, 2026. He was granted options to purchase 1,187 shares of common stock at an exercise price of $340.03 per share, expiring on September 13, 2036, which vest in full on September 14, 2027, subject to continued service on the Board and earlier vesting conditions under the company's Non-Employee Director Compensation Policy. He also received 471 restricted stock units, each representing a contingent right to one share of common stock, which vest in full on September 14, 2027 under the same service and policy conditions.

Insider Trade Summary

Grant/Award: 1,658 shares

Grant/Award 2 txns

Insider ROSSI DINO A

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) ^F1	1,187	$0.00	$0.00
Grant/Award	Restricted Stock Units ^{F2, F3}	471	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 1,187 contracts (Direct); Restricted Stock Units — 471 contracts (Direct)

Footnotes (3)

F1. The stock options vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant.
F2. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
F3. The RSUs vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant.

Key Figures

Stock options granted: 1,187 shares Option exercise price: $340.03 per share Option expiration date: September 13, 2036 +4 more

7 metrics

Stock options granted 1,187 shares Options to buy Krystal Biotech common stock granted to Dino A. Rossi on September 14, 2026

Option exercise price $340.03 per share Exercise price of options granted to Dino A. Rossi on September 14, 2026

Option expiration date September 13, 2036 Expiration date of options granted to Dino A. Rossi

Options held after grant 1,187 options Total options reported as held by Dino A. Rossi following the September 14, 2026 grant

Restricted stock units granted 471 RSUs RSUs granted to Dino A. Rossi on September 14, 2026

RSUs held after grant 471 RSUs Total RSUs reported as held by Dino A. Rossi following the grant

Vesting date September 14, 2027 Full vesting date for both the options and RSUs, subject to continued Board service

Key Terms

Restricted Stock Units, contingent right, Non-Employee Director Compensation Policy

3 terms

Restricted Stock Units financial

"Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Company's common stock."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

contingent right financial

"Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Company's common stock."

Non-Employee Director Compensation Policy financial

"described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did director Dino A. Rossi receive from KRYS on September 14, 2026?

He received stock options for 1,187 shares of Krystal Biotech common stock at an exercise price of $340.03 per share and 471 restricted stock units, each representing a contingent right to one common share.

When do Dino A. Rossi’s new Krystal Biotech (KRYS) stock options and RSUs vest?

Both the stock options and the 471 restricted stock units vest in full on September 14, 2027, subject to his continued service on Krystal Biotech’s Board of Directors and earlier vesting in certain circumstances described in the Non-Employee Director Compensation Policy.

What is the exercise price and expiration date of Dino A. Rossi’s new KRYS stock options?

The newly granted options have an exercise price of $340.03 per share and expire on September 13, 2036, according to Krystal Biotech’s disclosure.

How many Krystal Biotech (KRYS) shares underlie Dino A. Rossi’s new RSU grant?

The restricted stock unit grant covers 471 RSUs, and each RSU represents a contingent right to receive one share of Krystal Biotech’s common stock upon vesting, assuming service conditions are met.

Are Dino A. Rossi’s September 14, 2026 KRYS equity awards tied to a Rule 10b5-1 trading plan?

No. The filing does not report that these equity awards were granted or transacted under a Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 09/16/2026 - 08:05 PM Accepted by SEC EDGAR 09/16/2026 - 08:05 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ROSSI DINO A

(Last)

(First)

(Middle)

C/O KRYSTAL BIOTECH, INC.

2100 WHARTON STREET, SUITE 701

(Street)

PITTSBURGH

PENNSYLVANIA

15203

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Krystal Biotech, Inc. [ KRYS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$340.03	09/14/2026		A		1,187		⁽¹⁾	09/13/2036	Common Stock	1,187	$0	1,187	D
Restricted Stock Units	⁽²⁾	09/14/2026		A		471		⁽³⁾	⁽³⁾	Common Stock	471	$0	471	D

Explanation of Responses:

1. The stock options vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant.

2. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Company's common stock.

3. The RSUs vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant.

Remarks:

	/s/ Krish Krishnan, as attorney-in-fact for Dino A. Rossi	09/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

Krystal Biotech grants director options, 471 RSUs

Rhea-AI Filing Summary

Positive

Negative